{"entity":{"id":"nct04772287","kind":"trial","name":"Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)","aka":[],"tldr":"A phase 3 trial of toripalimab in lung cancer, run by Shanghai Pulmonary Hospital, Shanghai, China, not yet recruiting.","summary":"Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008) is a phase 3, randomised interventional study registered as NCT04772287 by Shanghai Pulmonary Hospital, Shanghai, China, with a registry enrolment figure of 341 participants, started 2021-03-31 and due to reach its primary completion in 2026-12-30. Interventions recorded: Toripalimab; Toripalimab mimetic (placebo). Conditions listed: Non Small Cell Lung Cancer. Primary outcome: Disease-free survival (DFS). Lung eligibility wording from the registry: \"Histological diagnosis of primary non-small cell lung cancer (NSCLC)\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT04772287","url":"https://clinicaltrials.gov/study/NCT04772287"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["egfr-mutant-nsclc","alk-positive-nsclc","resectable-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["toripalimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04772287","phase":"3","setting":"Adjuvant Toripalimab Versus Placebo Combined With Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) Non-small-cell Lung Cancer (LungMate-008): a Randomised, Double-blind, Controlled, Phase 3 Trial","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","enrolled":341,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04772287/","neighbours":{"cancer":[{"id":"alk-positive-nsclc","kind":"cancer","name":"ALK-positive non-small-cell lung cancer","route":"/cancers/alk-positive-nsclc/"},{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}